- Extraction: Earlier this month the Company announced breakthrough extraction results. For more information please refer to its news release dated December 12: https://abattis.com/2017/12/12/abattis-confirms-breakthrough-extraction-technology-capabilities/
- Financing: Over the past month, the Company has successfully raised over $8,500,000 in private placements and warrant exercises. These funds are expected to be used to aggressively grow the extraction business, and for laboratory expansion, acquisitions and general working capital.
- Acquisition: Earlier today, the Company announced its intent to purchase Green Tree Therapeutics via an acquisition of Winston Resources Inc. (" WRW"). Further details are set out below.
ON BEHALF OF THE BOARD OF ABATTIS BIOCEUTICALS CORP."Rob Abenante" Robert Abenante, President & CEO For more information, please visit the Company's website at: www.abattis.com For inquiries, please contact the Company at (604) 674-8232 or at firstname.lastname@example.org. Disclaimer for Forward-Looking Statements Certain information set out in this news release constitutes" forward-looking information" or "forward-looking statements", which may include information relating to the proposed financing of the Company and its use of proceeds. Forward-looking statements (often, but not always, identified by the use of words such as "expect", "may", "could", "anticipate", or "will", and similar expressions) may describe expectations, opinions or guidance that are not statements of fact and which may be based upon information provided by third parties. Forward-looking statements in this news release include statements regarding: the terms of the proposed Transaction; the Company's ability to enter into a definitive agreement in respect of and complete the proposed Transaction; the excepted benefits of integrating GTT under the Abattis business umbrella; and the potential therapeutic benefits of GTT's products. Forward-looking statements are based upon the opinions, expectations and estimates of management of the Company as at the date the statements are made and are subject to a variety of known and unknown risks and uncertainties and other factors that could cause actual events or outcomes to differ materially from those anticipated or implied by such forward-looking statements. Those factors include, but are not limited to: the risk that the parties may be unable to agree on terms for the definitive agreement; the risk that the Transaction may not be completed on the terms contemplated or at all; the risk that the Transaction may not obtain necessary approvals, including the approval of the Canadian Securities Exchange, the shareholders of GTT or the board of directors of any of the parties; regulatory and other risks associated with the cannabis industry; operational risks associated with development and production operations; risks related to delays or changes in plans and unanticipated costs and expenses, among others. In light of the risks and uncertainties associated with forward-looking statements; and other risks, uncertainties and other factors that are beyond the control of the Company. Although the Company believes that the expectations reflected in the forward-looking statements set out in this news release are reasonable, it can give no assurance that such expectations will prove to be correct, and readers are cautioned not to place undue reliance upon forward-looking information. The forward-looking statements of the Company contained in this news release are made only as at the date hereof and are expressly qualified, in their entirety, by this cautionary statement. Except as required by law, the Company does not undertake to update any forward-looking statement contained in this news release.